Sourcing checklist: what to look for before trusting a supplier

What separates a supplier producing a consistent, correctly identified product from one that is not is manufacturing and testing practice, which is largely invisible to a buyer at the point of purchase. Website quality, customer service responsiveness, and price are not reliable proxies for what is actually in the vial. This article lays out categories of information that are checkable before ordering, based on documented patterns in how substandard and falsified medical products are identified [1], while being explicit that none of these checks amount to direct proof of a specific vial's contents.

Independent testing documentation is the single most informative category. A certificate of analysis (COA) issued by the same company selling the product carries materially less weight than one from a named, independent, third-party analytical laboratory that can be looked up and confirmed to exist and to perform the type of testing claimed. Purity by high-performance liquid chromatography (HPLC) is a common baseline test, but it establishes how much of a sample matches the intended molecule relative to other similar compounds; it does not confirm the molecule's identity (which requires mass spectrometry or amino acid analysis) and does not address bacterial contamination (which requires sterility and endotoxin testing). A COA showing high purity by one method says nothing about the other two, and a COA that only reports one type of test should be read as partial information, not a clean bill of health.

Batch and lot tracking is a second checkable category. A supplier with real manufacturing and inventory control can typically identify which batch a given order came from and roughly when it was produced. The FDA has documented cases of fraudulent compounded product labels naming pharmacies that did not exist or did not actually produce the labeled product, which illustrates how label claims about sourcing and batch identity can be fabricated entirely, not merely inaccurate [2]. A label or a COA that cannot be traced to a verifiable, real entity is a documented pattern associated with falsified product, not a guarantee of it, and a batch number that never changes across months of reordering is itself worth questioning, since it suggests either the supplier is not actually tracking production runs or that inventory is sitting for extended periods before sale, which raises separate concerns about degradation.

Community-reported testing and reputation carry some value but real limitations. Independent groups that pool resources to send batches from popular suppliers to outside laboratories, when the methodology and the lab used are named and verifiable, provide more information than anecdote alone, because they add an actual analytical data point rather than relying on a supplier's self-reported claims. Their usefulness is bounded by time: a well-documented result from six months ago does not establish that a current batch from the same supplier is identical, since raw material sourcing, synthesis process, and storage conditions can all change between production runs without any external signal to a buyer. Review volume and sentiment are weaker signals still; fabricated reviews are a documented issue across online commerce generally, and the WHO explicitly identifies online and informal markets as common channels for substandard and falsified medical products, precisely because they sit outside the verification infrastructure of licensed pharmacy supply chains [1].

Packaging, labeling consistency, payment methods, and shipping conditions form a final, weaker but still informative category. Inconsistent labeling between orders, vial stoppers or crimp caps that vary between batches, or documentation with obvious errors point toward an operation that is not managing basic quality processes carefully, which is at minimum a signal that other, less visible processes such as synthesis quality control and sterility practice may not be handled carefully either. A supplier that accepts only payment methods offering little or no buyer recourse is, at minimum, structured in a way that limits a buyer's ability to dispute a bad transaction. Shipping conditions matter for any temperature-sensitive product: a supplier that ships in appropriate insulated or temperature-controlled packaging is investing in preserving product integrity in transit, while one that ships the same product in ordinary packaging regardless of season or distance is not managing a variable known to affect stability and potency.

It is useful to weigh these signals against each other rather than treat any single one as decisive. A supplier with polished packaging and a professional website but no independent test documentation at all should generally be weighted lower than a plainly packaged supplier that provides verifiable, named third-party lab results, because professionalism of presentation and analytical verification are not the same thing, and only one of them speaks directly to what is actually in the vial. Similarly, no single glowing review or absence of visible complaints should outweigh a missing or unverifiable COA, since fabricated reviews are cheap to produce and independent laboratory verification is not.

The genuine limitation to name clearly: even a supplier that checks every item above can still supply a substandard or falsified batch, and a buyer without access to independent laboratory testing of their specific vial cannot fully rule that out. The WHO's data placing at least 1 in 10 medical products in low- and middle-income countries as substandard or falsified describes a documented, global problem in far more regulated distribution channels than most online peptide sales, which is a reasonable basis for treating unregulated online peptide markets as at least comparably uncertain [1]. This checklist reduces risk relative to no diligence at all; it is not equivalent to independent verification and should not be treated as one.

One additional pattern worth checking for is consistency of the product itself over time, not just at the point of a single order. If a supplier's product changes appearance, vial type, stopper design, or labeling format between one order and the next without explanation, that is worth treating as a signal in its own right, since legitimate manufacturing changes are typically documented and explained by suppliers with real quality processes, while unexplained changes are more consistent with an operation sourcing product inconsistently from different, unverified origins.

It is also worth distinguishing between the regulatory tiers a product can fall into, since that affects how much of this checklist even applies. FDA-approved peptide medications sold through licensed pharmacies are manufactured under current Good Manufacturing Practice (cGMP) standards with ongoing regulatory inspection, which is a different oversight tier from anything a checklist like this can substitute for. Legally compounded products occupy a middle tier with lighter but still licensed oversight. Products sold explicitly as "research use only" or "not for human consumption" fall entirely outside that system, and the FDA's stated position is that these are unapproved drugs, meaning using them involves accepting risk that has not been evaluated through the standard drug approval process at all [3]. This checklist is aimed specifically at that last category, since it is the one with no regulatory floor underneath it.

In practical terms, applying the categories above (independent test documentation, traceable batch identity, verifiable community testing, and consistent labeling, payment, and shipping practices) is a reasonable way to reduce uncertainty about a given supplier relative to no diligence at all. It does not convert an unapproved, unregulated product into a verified one, and independent, batch-specific laboratory testing remains the only direct way to confirm what is actually in a given vial. Anyone weighing whether a specific product is appropriate for their situation, particularly alongside an existing medical condition or medication, is better served by discussing that decision with a clinician or pharmacist than by treating supplier diligence as a substitute for medical guidance.